Released Nov 4, 2025, after the close
10-Q filed Nov 4, 2025, 35 days after period end · 0001193125-25-264695
Q3 2025 · 10-Q
Revenue$19.55M$19.55M −11.5% vs Q3 2024−10.2% vs Q2 2025
Net Income-$34.69M-$34.69M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.09-$0.09 N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$9,484,000−21.8%
Operating Income-$32,938,000N/M
Operating Cash Flowderived-$22,202,000N/M
Free Cash Flowderived-$23,088,000N/M
Margins · derived
Gross margin48.5%−6.4 pt vs Q3 2024
Operating margin-168.5%−47.6 pt vs Q3 2024
Net margin-177.4%−55.4 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $19.55M | $22.09M | $25.37M | $25.65M |
| Net Income | -$34.69M | -$26.94M | -$21.00M | -$29.43M |
| EPS Diluted | -$0.09 | -$0.07 | -$0.27 | -$0.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR